Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Chronic Heart Failure (CHF)
Interventions: RLX030, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ulcerative Colitis
Interventions: BMS-986165, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 31
States / cities: Bristol, Connecticut • Gainesville, Florida • New Port Richey, Florida + 25 more

Conditions: HIV Infections
Interventions: Ranitidine hydrochloride; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Sherman Oaks, California • Coral Gables, Florida • Durham, North Carolina + 1 more

Conditions: Back Pain, Neck Pain, Sleep Initiation and Maintenance Disorders
Interventions: Magnetic Sleep Pad; Device
Lead sponsor: Weintraub, Michael I., MD, FACP, FAAN; Individual
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Briarcliff Manor, New York

Conditions: Human Papilloma Virus, Dysplasia, CIN1, CIN2
Interventions: AHCC 3 grams once a day, Placebo; Dietary Supplement · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more

Conditions: Metabolic Acidosis
Interventions: TRC101, Placebo; Drug
Lead sponsor: Tricida, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 9 more

Conditions: Acute Myocardial Infarction
Interventions: BAY2433334, BAY2433334 matching placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 1,601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Covina, California • Boynton Beach, Florida • Clearwater, Florida + 19 more

Conditions: Language Disorders
Interventions: Self Study Journal Club, Intensive Journal Club; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Antihistamine, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 24
States / cities: Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more

Conditions: Knee Osteoarthritis
Interventions: iovera°, Sham Comparator; Device
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Covina, California • Sacramento, California • Bradenton, Florida + 14 more

Conditions: Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Interventions: Ranirestat, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Refractory IPA
Interventions: PC945, Placebo; Drug
Lead sponsor: Pulmocide Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Herpes Simplex Type II
Interventions: TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obstructive Sleep Apnea
Interventions: Montelukast; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 2 Years to 10 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer, Acute Lymphoblastic Leukemia, Lymphoma, Sarcoma, Acute Myelogenous Leukemia, Brain Tumors, Germ Cell Tumor
Interventions: Promoting Resilience In Stress Management (PRISM); Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 13 Years to 25 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Liver Cirrhosis
Interventions: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas

Conditions: Infection Prophylaxis
Interventions: SAR279356, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Jacksonville, Florida + 3 more

Conditions: Hypertension (HTN), Food Insecurity
Interventions: Produce Prescription Only, Community Health Worker navigated Produce Prescription; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 20 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Honokaa, Hawaii • Waianae, Hawaii • Waimanalo, Hawaii

Conditions: Esophageal Subepithelial Lesions
Interventions: 22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC), conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass); Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus Type 1
Interventions: ORMD-0801 Capsules, Placebo; Biological · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Tustin, California

Conditions: Acute Ischemic Stroke From Large Vessel Occlusion
Interventions: Penumbra System with Separator 3D, Penumbra System alone; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 8
States / cities: Newport Beach, California • Denver, Colorado • Hartford, Connecticut + 5 more

Conditions: Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions: Linsitinib, Placebo; Drug
Lead sponsor: Sling Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Beverly Hills, California • La Jolla, California • Los Angeles, California + 15 more

Search by objective public record fields.

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

Study on Magnetic Field Therapy to Improve Quality of Sleep and Reduction of Chronic Spine Pain

Phase II Evaluation of AHCC for the Eradication of HPV Infections

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

China Obstetrics and Gynecology Journal Club

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain

Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children

A Pilot RCT of the PRISM Intervention for AYAs With Cancer

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

Navigating Hypertension and Food Insecurity

EUS-CNB Versus EUS-SINK for Diagnosis of Upper Gastrointestinal (UGI) Subepithelial Tumors

A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)